HOME / Imprensa / Press Releases / INTERNACIONAIS

INTERNACIONAIS

26 abril 2017

Fresenius Kabi to strenghthen and diversify product portfolio by acquiring Akorn and Merck KGaA's biosimilars business

Stephan Sturm, CEO of Fresenius, said: “From a position of strength, Fresenius Kabi enhances and complements its business with two major steps. Akorn is an excellent strategic fit for Fresenius Kabi. 

 

3 fevereiro 2017

Fresenius Medical Care acquiring a majority stake in Cura Group and scales up in Australia

Fresenius Medical Care, the world’s largest provider of dialysis products and services, acquires a majority stake in Cura Group ("Cura"), a leading operator of high-quality day hospitals in Australia.

 

31 janeiro 2017

Fresenius Medical Care reaches agreement on outstanding payments

Fresenius Medical Care Holdings, Inc. (the “Company”), the North American subsidiary of Fresenius Medical Care AG & Co. KGaA (“FMC”), has reached an amicable agreement with the United States Departments of Veterans Affairs and Justice resolving reimbursement for services provided to veterans by the Company’s clinics during the period January 2009 through February 15, 2011.

 

26 janeiro 2017

U.S. District Issues Preliminary Injunction Against Premium Assistance Regulation

Fresenius Medical Care Holdings, Inc. (FMCNA) has joined other United States dialysis providers and patient advocates in filing a lawsuit challenging the rulemaking process used by the United States Centers for Medicare and Medicaid Services (CMS) to promulgate a new regulation regarding premium assistance programs that help to fund health insurance premiums for U.S. patients with end stage renal disease (ESRD).

 

7 janeiro 2017

Statement of Fresenius Medical Care Regarding Lawsuit Challenging Premium Assistance Regulation 

Fresenius Medical Care Holdings, Inc. (FMCNA) has joined other United States dialysis providers and patient advocates in filing a lawsuit challenging the rulemaking process used by the United States Centers for Medicare and Medicaid Services (CMS) to promulgate a new regulation regarding premium assistance programs that help to fund health insurance premiums for U.S. patients with end stage renal disease (ESRD).

 

2 dezembro 2016

Change in investor Relations Management - Dr. Dominik Heger joins Fresenius Medical Care

Dr. Dominik Heger will join Fresenius Medical Care, the world’s largest provider of dialysis products and services, as Senior Vice President and Head of Investor Relations and Corporate Communications effective January 5, 2017.

 

1 dezembro 2016

Fresenius will focus on IFRS reporting starting fiscal year 2017

Fresenius SE & Co. KGaA (“Fresenius”) will focus its reporting on financial statements in accordance with International Financial Reporting Standards (IFRS) starting with the 2017 fiscal year on January 1, 2017. The company will then no longer provide U.S. GAAP financial information.

 

1 dezembro 2016

Fresenius Medical Care will focus in IFRS reporting and discontinue U.S. GAAP financial statements

Fresenius Medical Care AG & Co. KGaA will focus its reporting on financial statements in accordance with International Financial Reporting Standards (IFRS) in Euro currency starting with the 2017 fiscal year on January 1, 2017. The company will then no longer provide U.S. GAAP financial information.

 

10 outubro 2016

Fresenius Medical Care celebrates 20th anniversary

Fresenius Medical Care, the world’s largest provider of dialysis products and services, is celebrating its 20th anniversary. 

 

2 setembro 2016

Fresenius Medical Care acquires dialysis service provider Sandor Nephro Services in India

Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced to acquire 85% of equity interest in Indian dialysis group Sandor Nephro Services from a group of investors. The parties involved agreed not to disclose financial terms of the transaction.

 

1 agosto 2016

Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter

“Following a solid start to the year, we have accelerated our growth in the second quarter”, said Rice Powell, Chief Executive Officer of Fresenius Medical Care. “Our strong earnings growth demonstrates our ability to further improve our cost base and the success of our Global Efficiency Program. I am extremely pleased with our excellent operational performance in the core dialysis services business.

 

1 agosto 2016

Fresenius raises earnings guidance after strong second quarter; Double-digit earnings growth

Stephan Sturm, CEO of Fresenius, said: “Once again, all four business segments contributed to strong organic growth. This confirms Fresenius’ sound strategic position as a healthcare Group. We have continued to grow even in regions where economies have slowed. This confirms the stability of our markets and businesses.

 

31 maio 2016

Fresenius Medical Care establishes regenerative medicine subsidiary, to continue successful work with University of Turin

Fresenius Medical Care, the world’s largest provider of dialysis products and services, has established a subsidiary focusing on regenerative medicine. Unicyte AG will pursue research into kidney and liver diseases, diabetes and cancer, and will work with additional partners when needed to advance these projects.

 

25 maio 2016

Fresenius Medical Care launches 6008 CAREsystem, a new hemodialysis therapy system enabling better care for chronic patients

Fresenius Medical Care, the world’s largest provider of dialysis products and services, has launched the 6008 CAREsystem for the treatment of patients with end-stage renal disease (ESRD). This new dialysis therapy system incorporates Fresenius Medical Care’s highest therapy standards while optimizing dialysis treatment and improving economic efficiency. Most importantly, it minimizes the number of risk-related handling steps and reduces complexity in therapy delivery. 

 

12 maio 2016

Fresenius Medical Care expects continued, stong growth -  Annual General Meeting approves consecutive dividend increase

Fresenius Medical Care, the world’s leading provider of dialysis products and services, expects significant sales and earnings growth in 2016. At the Annual General Meeting in Frankfurt today, CEO Rice Powell confirmed the full-year guidance announced in February. The company is targeting 7 to 10 percent revenue growth in constant currency, and an increase in net income of 15 to 20 percent. 

 

11 março 2016

Fresenius Medical Care anounces proposals for election to the Supervisory Board by the Annual General Meeting on May 12, 2016

The Supervisory Board of Fresenius Medical Care AG & Co. KGaA has decided in its meeting on March 9, 2016, to propose to the Annual General Meeting on May 12, 2016 the following candidates for regular election to the Supervisory Board 

 

18 fevereiro 2016

Fresenius Medical Care reaches agreement in principle to resolve the GranuFlo®/NaturaLyte® product liability litigation 

Fresenius Medical Care AG & Co. KGaA (“the company” or “Fresenius Medical Care”), the world’s largest provider of dialysis products and services, today announced that Fresenius Medical Care North America (FMCNA) has reached an agreement in principle with a committee designated by the plaintiffs to resolve litigation in the United States involving GranuFlo®®/NaturaLyte. 

 

10 dezembro 2015

Fresenius lauches new corporate website

Fresenius has put its new website online: www.fresenius.com. The relaunched website combines technology and design in a modern, user-friendly Internet format. The content has been updated and rearranged, with easy-to-use navigation. Powerful photographs on the homepage will guide visitors to interesting topics. The responsive design optimizes the display of all content on mobile devices and ensures quick loading times. 

 

29 outubro 2015

Continued strong sales and net income growth – Fresenius raises Group earnings guidance for 2015

Ulf Mark Schneider, CEO of Fresenius, said: “Our strong growth trend continued with doubledigit constant currency sales and earnings growth in the first nine months. All business segments contributed to the excellent financial results. Fresenius Kabi in particular stood out, benefiting from drug shortages and new product launches in the U.S. market. We raise our Group earnings guidance for 2015 and remain optimistic about the positive fundamentals in our markets.”

 

1 setembro 2015

Fresenius Medical Care releases new adsorder IgEnio® in Europe for treatment of severe allergic symptoms

Fresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market.
Latest epidemiological data shows that IgE-mediated diseases affect more than 25 percent of the world’s population. Of this group, an estimated 10 percent suffer from severe allergic symptoms such as asthma and atopic dermatitis. The new adsorber, called IgEnio®, is intended to provide a therapy option for these patients.

 

1 setembro 2015

Fresenius joins EURO STOXX 50 index

Fresenius SE & Co KGaA will be included in the EURO STOXX 50 blue-chip index on September 21, 2015. The index update was announced by the Deutsche Börse subsidiary STOXX after the close of trading on Monday night. The EURO STOXX 50 index tracks the share price development of 50 large publicly traded companies, representing various economic sectors, from twelve Eurozone countries.

 

27 agosto 2015

Fresenius expects 2015 dividend increase of more than 20%, will reach mid-term Group net income target ahead of schedule

Fresenius expects a significant 2015 dividend increase, resulting from the forecasted 2015 net income growth applied to the company’s dividend policy. After raising guidance twice this year, Fresenius is forecasting 2015 net income growth of 18% to 21% in constant currency. In addition, the company expects a significant positive currency effect. 2015 dividend growth is therefore expected to clearly exceed 20%. This will mark the company’s 23rd consecutive year of dividend increases.

 

20 maio 2015

Fresenius SE & Co. KGaA Annual General Meeting: 2015 guidance confirmed, 22nd consecutive dividend increase approved

Fresenius expects to set new sales and earnings records in 2015. Ulf Mark Schneider, CEO of Fresenius, confirmed the company’s growth targets at the Annual General Meeting in Frankfurt today. The global healthcare group forecasts sales growth of 7 to 10 percent and an increase in net income of 13 to 16 percent this year, both in constant currency. After a strong first quarter, Fresenius had raised its earnings guidance in April. 

 

18 maio 2015

Fresenius Medical Care confirms growth targets – Shareholders approve 18th consecutive dividend increase

Fresenius Medical Care, the world’s largest provider of dialysis products and services, is aiming to increase sales and earnings in the coming years. At today’s Annual General Meeting in Frankfurt, chief executive officer Rice Powell confirmed the company’s growth targets for 2015 and beyond. Revenue is expected to increase by 10 to 12% in constant currency and net income by up to 5%. In 2016, the company expects net income to grow by 15 to 20%, and revenue to increase by 9 to 12% in constant currency. 

 

4 maio 2015

Fresenius Medical Care introduces multiFiltratePRO, a new therapy system for acute dialysis ​

Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, has launched multiFiltratePRO, a therapy system for continuous renal replacement therapy (CRRT), for the treatment of acute kidney failure in critically ill patients at intensive care units. 

 

25 fevereiro 2015

Sales and net income reach all-time highs – 6% dividend increase proposed – Positive Group outlook for 2015

Ulf Mark Schneider, CEO of Fresenius, said: „2014 was a challenging but successful year for Fresenius. We made significant progress on the integration of the Rhön hospitals, strengthened the Care Coordination initiatives at Fresenius Medical Care, and set new sales and earnings records for the Group. Fresenius sees significant opportunities arising from the increasing demand for affordable, high-quality health care around the globe. We remain highly optimistic about the growth prospects in all our business segments for 2015 and beyond.”

 

19 janeiro 2015

Fresenius refinances its credit agreement - Standard & Poor's upgrades Fresenius' credit rating to investment grade

Fresenius has launched a refinancing of the revolving facilities and the term loan A tranches (aggregate volume approx. €3 bn) under its 2013 senior credit agreement. The maturity will be extended by 2 years to June 28, 2020. Given the improved credit profile and favorable bank market conditions, Fresenius’ proposal also includes reduced credit margins.

 

27 novembro 2014

Fresenius Medical Care successfully upsizes and extends the maturity of its credit agreement and also extends the maturity of its accounts receivable facility

Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, has upsized its syndicated credit facility by 850 million U.S. dollar equivalent to a total amount of approximately 4.4 billion U.S. dollar equivalent, with pricing and other conditions more favorable to the company. The amended credit facility consists of revolving facilities and term loans, both U.S. dollar and euro denominated. The final maturity date was extended by two years to October 30, 2019. The facilities will be used to refinance existing debt, for working capital needs and general corporate purposes. 

 

13 novembro 2014

Fresenius Medical Care Announces Agreement to Acquire Cogent Healthcare

Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS) announced today that Sound Physicians Inc. (Sound) has entered into an agreement to acquire Cogent Healthcare (Cogent) with more than 650 providers, who offer hospitalist and intensivist services to more than 80 hospitals throughout the United States. Combined, the expanded Sound Physicians organization will now serve over 180 hospitals in 35 states with more than 2,250 providers including physicians and advanced care practitioners. Fresenius Medical Care is the majority shareholder in Sound.

 

23 outubro 2014

Fresenius nominates Allianz CEO Michael Diekmann for Supervisory Board

The Supervisory Board of Fresenius SE & Co. KGaA will propose that the next Annual General Meeting elect Mr. Michael Diekmann to the Supervisory Board. The Supervisory Board believes that his immense expertise and experience qualify Mr. Diekmann for the position of Deputy Chairman, which is now vacant. If elected to the Board, Mr. Diekmann has declared that he will seek this post.

 

23 outubro 2014

Fresenius Medical Care expands further in care coordination with the acquisition of National Cardiovascular Partners

Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced the acquisition of National Cardiovascular Partners (“NCP”). The parties involved agreed not to disclose the financial terms of the acquisition.

 

15 setembro 2014

Fresenius Medical Care introduces new sleep safe harmony cycler for a Peritoneal Dialysis therapy tailored to patients' needs

Fresenius Medical Care, the world’s largest provider of dialysis products and services, has launched a new cycler that delivers a Peritoneal Dialysis (PD) therapy tailored to individual patients’ needs. sleepsafe harmony was presented to leading specialists from around the world at two scientific congresses in Berlin and Madrid on September 6 and 7. The device is available from now on in selected countries including Germany, Spain, Great Britain and France. 

 

27 junho 2014

Fresenius Medical Care Makes Strategic Investments in Care Coordination

Company executes on the strategy disclosed earlier this year to invest in care coordination around dialysis. The investment clearly advances the commitment to address the full spectrum of care for chronically ill patients.

 

16 maio 2014

Fresenius SE & Co. KGaA Annual General Meeting:Stock split and 21st consecutive dividend increase approved 

A large majority of 99.48% Fresenius SE & Co. KGaA shareholders approved a three-for-one stock split at the company’s Annual General Meeting in Frankfurt today. Every shareholder will receive two additional shares for each share held.

 

15 maio 2014

Fresenius Medical Care confirms long-term growth targets - Shareholders approve 17th consecutive dividend increase

Fresenius Medical Care expects continued strong growth in the coming years. At today’s Annual General Meeting in Frankfurt, Rice Powell, chief executive officer, confirmed the long-term targets announced in April.

 

15 abril 2014

Fresenius Medical Care and Joslin Diabetes Center Partner to Improve Health of Patients with Diabetic Kidney Disease

Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, and Joslin Diabetes Center, Inc., the world's preeminent diabetes research, clinical care and education organization, announced an agreement today to jointly develop renal care programs in select Joslin Affiliated Centers for patients with diabetic kidney disease (DKD).

 

12 março 2014

Fresenius Medical Care Announces Management Board Changes

Fresenius Medical Care, the world's largest provider of dialysis products and services, today announced two changes in the Management Board.

 

25 fevereiro 2014

Fresenius Medical Care reports fourth quarter and full year 2013 results

Targets achieved for fiscal year 2013 - Further expansion of global franchise and new record level of revenue - Increased dividend to be proposed at the Annual General Meeting.

 

5 novembro 2013

Fresenius Medical Care Reports Third Quarter And Nine Months

Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME/New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced its results for the third quarter and first nine months of 2013.

 

2 setembro 2013

First Environmental Award in Renal Care Awarded by EDTNA / ERCA and Fresenius Medical Care

Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius, will celebrate his 75th birthday on October 8. Before he moved to the Supervisory Board in 2003, Dr. Krick spent almost three decades in top management positions at Fresenius, including 11 years as Chief Executive Officer.

 

30 julho 2013

Fresenius Medical Care Reports Second Quarter And Half Year 2013 Results

Fresenius Medical Care AG & Co today announced its results for the second quarter and first half of 2013.

NephroCare
Trabalhar na Fresenius
NA
© Fresenius Medical Care Portugal
by Bluesoft.pt